OCEA · Ocean Biomedical, Inc.
$0.01
-0.01 (-52.20%)
At close · Apr 24
Going-concern doubt
— flagged May 15, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These events and conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”View the 10-Q filed May 15, 2025
Market Cap
$348,547
Shares
232.37M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Elizabeth Ng | Chief Executive Officer | $6,811,560 |
| Daniel Behr | Executive Vice President and Head of External Innovation and Academic Partnerships | $3,405,780 |
| Jonathan Heller | Former Chief Science Officer and Head of Research and Development | $1,702,890 |
| Gurinder Kalra | Chief Financial Officer | $1,135,260 |
| Inderjote Kathuria | Chief Strategy Officer | $1,135,260 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Gurinder Kalra | Chief Financial Officer | — |
| Jonathan Heller | Former Chief Science Officer and Head of Research and Development | — |
| Inderjote Kathuria | Chief Strategy Officer | — |
| Daniel Behr | Executive Vice President and Head of External Innovation and Academic Partnerships | — |
| Elizabeth Ng | Chief Executive Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jolie Kahn | CFO | Resigned | 2025-08-05 |
| Michael Petersen | director | Resigned | 2025-08-05 |